ROKIT Healthcare presented clinical outcomes of an AI bioprinting-based autologous fat tissue regeneration therapy for skin cancer reconstruction at EWMA 2026 in Bremen, Germany, during the conference held 6 May to 8 May, with results disclosed in a 7 May session.
The company reports no tumor recurrence in patients followed for up to 2 years and documents functional recovery of excision sites, aesthetic improvement, restoration of sensation and reduced scarring compared with conventional grafting or suturing approaches.
ROKIT Healthcare also highlighted demonstrations of its AI regeneration platform that converts lesion scans into regenerative patches and said it is negotiating partnerships with hospitals and medical device distributors in Europe, including Germany and France, and aims to sign three partners in Europe and the Middle East in the first half of the year.
The company noted that Europe has a high incidence of skin cancer and that a shift to autologous tissue regeneration could lower treatment costs; it intends to extend the technology beyond diabetic foot and skin cancer to organ targets such as cartilage and the kidneys.
Source: https://www.asiae.co.kr/en/article/2026050608460637200
